AlzeCure Pharma AB announced that the company’s CEO Martin Jönsson will participate in Redeye’s event focused on Alzheimer’s disease between 2 p.m. and 3 p.m. CET on March 21, 2024.
STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates for CNS diseases, focusing on Alzheimer’s disease and pain, announced today that the company’s CEO Martin Jönsson will participate in Redeye’s event focused on Alzheimer’s disease between 2 p.m. and 3 p.m. CET on March 21, 2024.
AlzeCure, along with Bioarctic and Alizinova, have been invited to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it takes to successfully launch a new generation of Alzheimer’s drugs.
Each company opens with a one-minute presentation and then participates in a 10-minute Q&A led by Redeye’s analyst. Martin Jönsson begins his presentation at 14.20. The event, which is in Swedish, ends with a panel discussion in which all companies participate.
The live broadcast is available via the following link: https://www.redeye.se/events/975970/redeye-theme-alzheimer-2
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies.
FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.
About Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia, affecting approximately 55 million people worldwide. Alzheimer’s disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer’s are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about $1,300 billion globally in 2019. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute.The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer’s disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer’s disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure to partake in Redeye Theme: Alzheimer on March 21
SOURCE: AlzeCure Pharma
View the original press release on accesswire.com
